drugset / Trial / NCT05044117
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
Phase 3
Recruiting
220 enrolled
Sun Yat-sen University
Affiliated Hospital of Guangdong Medical University · collabFujian Medical University Union Hospital · collabGuangzhou Panyu Central Hospital · collabHanzhong Central Hospital · collabHunan University of Medicine General Hospital · collabJiangmen Central Hospital · collabThe Central Hospital of Yongzhou · collabXiangyang No.1 People's Hospital · collabYichang Central People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate whether the addition of metronomic capecitabine to the standard treatment can improve prognosis in locoregionally advanced head and neck squamous cell carcinoma.
Timeline
- Start
- 2021-10-18
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 650 mg/m2 | Oral |